Market Overview

UBS: Buy Biogen For Pipeline, M&A Potential

UBS: Buy Biogen For Pipeline, M&A Potential
Related BIIB
Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More
These Are The Biggest Stocks Reporting Earnings This Week, And Their Recent Track Records
ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q3 2018 (Seeking Alpha)

Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside. 

The Rating

UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410.

The Thesis

Biogen’s existing pipeline and potential asset acquisitions through 2018 present a $45-a-share opportunity, Gould said in a Wednesday note. 

Stabilization of the biotech’s multiple sclerosis business, clarity on negative Spinraza growth and 2019 data on the aducanumab Alzheimer’s trial affirm the “core pillars” of Biogen valuation and earnings per share estimates and positively skew the risk-reward, the analyst said.

“The current share price still implies minimal (if any) value for these assets,” the analyst said. “While these are high-risk programs, they (1) all have blockbuster potential, and (2) are not in Street models — implying success for any one likely drives upside from here.”

The pipeline compounds “increasing likelihood” that Biogen buys new assets with its $37-billion in capital, Gould said. 

The analyst said he expects a 2018 focus on the midstage neurology portfolio with trial results for stroke, neuropathic pain, Parkinson’s disease and amyotrophic lateral sclerosis. The indications are presently excluded from Street models and together represent a sales opportunity between $9 billion and $17 billion, according to UBS. 

Price Action

At the time of publication, shares were set to open up 1.4 percent at $357.55.

Related Links:

Here's Why Forward Pharma Lost 30% Today

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Latest Ratings for BIIB

Oct 2018JP MorganMaintainsOverweightOverweight
Oct 2018BernsteinDowngradesOutperformMarket Perform
Oct 2018Cantor FitzgeraldReinstatesOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: alzheimer's treatment Carter GouldAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (BIIB)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

ETFs: Focusing On Financials In February

Benzinga's Top Upgrades, Downgrades For January 31, 2018